RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin, Zotatifin and Gedatolisib

Summary

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (also known as Glucophage®) * Zotatifin (also known as eFT226) * Gedatolisib (also known as PF-05212384)

Description

Eligibility

Age range

18+ years

Sex

Female

Healthy volunteers

No

Interventions

• Drug
  Letrozole

  Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

• Drug
  Abemaciclib

  Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.

• Drug
  LY3023414

  LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.

• Drug
  Metformin

  Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.

• Drug
  Zotatifin

  Zotatifin is a selective eukaryotic initiation factor 4A (eIF4A) inhibitor.

• Drug
  Gedatolisib

  Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.

Locations (3)